28 related articles for article (PubMed ID: 17131463)
1. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
2. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
3. Site-directed late-stage diversification of macrocyclic nannocystins facilitating anticancer SAR and mode of action studies.
Zhang H; Tian Y; Yuan X; Xie F; Yu S; Cai J; Sun B; Shan C; Zhang W
RSC Med Chem; 2023 Feb; 14(2):299-312. PubMed ID: 36846368
[TBL] [Abstract][Full Text] [Related]
4. Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity.
Gerninghaus J; Zhubi R; Krämer A; Karim M; Tran DHN; Joerger AC; Schreiber C; Berger LM; Berger BT; Ehret TAL; Elson L; Lenz C; Saxena K; Müller S; Einav S; Knapp S; Hanke T
bioRxiv; 2024 Feb; ():. PubMed ID: 38405908
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclization
Zhang P; Jiang Z; Fan Z; Li G; Ma Q; Huang J; Tang J; Xu X; Yu JQ; Jin Z
Chem Sci; 2023 Aug; 14(31):8279-8287. PubMed ID: 37564415
[TBL] [Abstract][Full Text] [Related]
6. An Intriguing Purview on the Design of Macrocyclic Inhibitors for Unexplored Protein Kinases through Their Binding Site Comparison.
Bhujbal SP; Hah JM
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513921
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Docking Studies of Novel Macrocyclic Pentapeptides as Anticancer Multi-Targeted Kinase Inhibitors.
Amr AEE; Abo-Ghalia MH; Moustafa GO; Al-Omar MA; Nossier ES; Elsayed EA
Molecules; 2018 Sep; 23(10):. PubMed ID: 30241374
[TBL] [Abstract][Full Text] [Related]
8. Computational Macrocyclization: From de novo Macrocycle Generation to Binding Affinity Estimation.
Wagner V; Jantz L; Briem H; Sommer K; Rarey M; Christ CD
ChemMedChem; 2017 Nov; 12(22):1866-1872. PubMed ID: 28977738
[TBL] [Abstract][Full Text] [Related]
9. Modular, One-Pot, Sequential Aziridine Ring Opening-S(N)Ar Strategy to 7-, 10-, and 11-Membered Benzo-Fused Sultams.
Loh JK; Asad N; Samarakoon TB; Hanson PR
J Org Chem; 2015 Oct; 80(20):9926-41. PubMed ID: 26446396
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Wrasidlo W; Crews LA; Tsigelny IF; Stocking E; Kouznetsova VL; Price D; Paulino A; Gonzales T; Overk CR; Patrick C; Rockenstein E; Masliah E
Br J Pharmacol; 2014 Dec; 171(24):5757-73. PubMed ID: 25117211
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
[TBL] [Abstract][Full Text] [Related]
12. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
13. Pyrimidines as the potential circulatory drugs.
Cieplik J
Acta Pol Pharm; 1992; 49(4):67-71. PubMed ID: 16092438
[TBL] [Abstract][Full Text] [Related]
14. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
15. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
16. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
